Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript

Oct 28, 2021 / 06:30PM GMT
Release Date Price: $77.04 (+6.32%)
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst

Good afternoon, everyone. Thank you for joining us at the Jefferies Gene Therapy Summit. I have the pleasure of hosting Hank from BioMarin, the Head of BioMarin's R&D engine, and I really appreciate him taking the time to join with us, especially right after earnings which is always kind of a crazy time. So thanks so much, Hank.

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Pleasure.

Questions & Answers

Akash Tewari
Jefferies LLC, Research Division - Equity Analyst

Now -- and by the way, I'm Akash Tewari, a senior analyst covering biotech at Jefferies. So because it's a Gene Therapy Summit, I think it's only fair that let's start off by talking a little bit about vosoritide. But like I think obviously, there's -- you have 2 very critical FDA approval decisions, one on ROCTAVIAN, one on VOXZOGO.

I think on the call yesterday, a question that I feel like we were honing in on and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot